Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Companyâ€™s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Companyâ€™s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.

Employees

178

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/03/26	21.28 $	-0.23%	7,286,967
09/03/26	21.33 $	+0.61%	12,247,387
06/03/26	21.20 $	+65.88%	78,373,817
05/03/26	12.78 $	-0.70%	2,892,351
04/03/26	12.87 $	+28.32%	12,276,293

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

21.28USD

Average target price

21.50USD

Spread / Average Target

+1.03%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 20:00:00 10/03/2026 GMT			5-day change	1st Jan Change
21.28 ^USD	-0.23%		+112.16%	+128.33%

03-06	Health Care Down, but not by Much, Amid Defensive Bias - Health Care Roundup	DJ
03-06	US Equity Indexes Fall Amid Jobs Data Surprise, Rising Oil Prices	MT

Capitalization	2.2B 1.89B 1.71B 1.63B 2.98B 202B 3.08B 20.1B 8.05B 96.8B 8.25B 8.07B 347B	P/E ratio 2026 *	-27.3x	P/E ratio 2027 *	-138x
Enterprise value	2.05B 1.76B 1.59B 1.52B 2.78B 188B 2.87B 18.71B 7.49B 90.1B 7.68B 7.52B 323B	EV / Sales 2026 *	8.51x	EV / Sales 2027 *	6.59x
Free-Float	82.99%	Yield 2026 *	-	Yield 2027 *	-

03-06	Health Care Down, but not by Much, Amid Defensive Bias - Health Care Roundup	DJ
03-06	US Equity Indexes Fall Amid Jobs Data Surprise, Rising Oil Prices	MT
03-06	Top Midday Gainers	MT
03-06	Servier Pharmaceuticals LLC entered into a definitive agreement to acquire Day One Biopharmaceuticals, Inc. for $2.3 billion.	CI
03-06	Top Midday Stories: Gap Falls on Fiscal Q4 Results; Shell-Venezuela Oil Deals; Jefferies Calls Western Alliance Suit 'Without Merit'	MT
03-06	Wedbush Downgrades Day One Biopharmaceuticals to Neutral From Outperform, Cuts Price Target to $21.50 From $30	MT
03-06	Day One Biopharmaceuticals Shares Surge After Agreement to Be Acquired by Servier for $2.5 billion	MT
03-06	Day One Biopharmaceuticals Inc co to pay Servier Pharmaceuticals termination fee of $87.7 million if deal is terminated under certain circumstances	RE
03-06	Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push	RE
03-06	Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion	RE
03-06	Day One Biopharmaceuticals Agrees to Be Acquired by Servier for $2.5 billion	MT
03-06	Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's Rare Oncology Portfolio	RE
03-06	Day One Biopharmaceuticals to be acquired by Servier in $2.5 Billion Deal	MT

03-10	HC Wainwright Downgrades Day One Biopharmaceuticals to Neutral From Buy, Adjusts PT to $21.50 From $22	MT
03-06	Wedbush Downgrades Day One Biopharmaceuticals to Neutral From Outperform, Cuts Price Target to $21.50 From $30	MT
02-25	Wedbush Raises Price Target on Day One Biopharmaceuticals to $30 From $29, Keeps Outperform Rating	MT
11-13	Wedbush Adjusts Price Target on Day One Biopharmaceuticals to $29 From $25, Maintains Outperform Rating	MT
11-10	Day One Biopharmaceuticals, Inc. Announces New OJEMDA (tovorafenib) Data to Be Presented in Oral Session at the 2025 Society for Neuro-Oncology Annual Meeting	CI

Day One Biopharmaceuticals, Inc. Share Price

Equities

DAWN

US23954D1090

Pharmaceuticals

Valuation: Day One Biopharmaceuticals, Inc.

Chart: Day One Biopharmaceuticals, Inc.

Latest news: Day One Biopharmaceuticals, Inc.

Last Transcript: Day One Biopharmaceuticals, Inc.

Analysts' recommendations: Day One Biopharmaceuticals, Inc.

Press Releases: Day One Biopharmaceuticals, Inc.

News in other languages: Day One Biopharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Day One Biopharmaceuticals, Inc.

ETFs: Day One Biopharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-09	BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Talkspace, Inc. (Nasdaq - TALK), Day One Biopharmaceuticals, Inc. (Nasdaq - DAWN), Kennedy-Wilson Holdings, Inc. (NYSE - KW), United Homes Group, Inc. (Nasdaq - UHG)	AQ
03-06	Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN	BU
03-06	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)	NE
03-06	Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio	GL
02-24	Day One Biopharmaceuticals : Q4 2025 Earnings Call	PU

02-27	Ipsen : le CHMP rend un avis favorable sur l'Ojemda pour une tumeur cérébrale rare
25/07/24	Ipsen acquiert les droits d'un traitement contre la tumeur cérébrale chez l'enfant

1 day	-0.23%
1 week	+112.16%
Current month	+100.75%
1 month	+86.34%
3 months	+150.06%
6 months	+193.11%
Current year	+128.33%

1 week	12.5	21.43
1 month	9.97	21.43
Current year	8.35	21.43
1 year	5.64	21.43
3 years	5.64	21.43
5 years	5.44	28.7
10 years	5.44	28.7

Manager	Title	Age	Since
Jeremy Bender CEO	Chief Executive Officer	54	31/08/2020
Charles York DFI	Director of Finance/CFO	49	31/01/2021
Heather Huet CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Jeremy Bender BRD	Director/Board Member	54	31/08/2020
Natalie Holles BRD	Director/Board Member	53	31/01/2021
John Josey BRD	Director/Board Member	65	31/08/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
DAY ONE BIOPHARMACEUTICALS, INC.	-0.23%	+112.16%	+163.69%	+18.55%	2.2B
ELI LILLY AND COMPANY	-0.70%	-0.63%	+20.68%	+217.87%	895B
JOHNSON & JOHNSON	+0.46%	-1.23%	+45.32%	+60.75%	587B
ABBVIE INC.	-0.19%	-2.93%	+4.78%	+51.63%	401B
ROCHE HOLDING AG	+0.84%	-5.68%	+9.04%	+27.14%	345B
NOVARTIS AG	-2.63%	-3.48%	+20.34%	+63.50%	300B
ASTRAZENECA PLC	+1.47%	-1.86%	+23.75%	+36.98%	306B
MERCK & CO., INC.	-0.02%	-2.29%	+22.95%	+8.73%	289B
AMGEN INC.	-0.41%	-0.42%	+14.68%	+64.76%	202B
GILEAD SCIENCES, INC.	+1.32%	+0.49%	+26.75%	+86.87%	184B
Average	-0.01%	+9.41%	+35.20%	+63.68%	351.27B
Weighted average by Cap.	-0.09%	-1.84%	+22.33%	+91.87%

	2026 *	2027 *
Net sales	240M 206M 187M 179M 326M 22.09B 337M 2.2B 880M 10.59B 902M 883M 37.91B	308M 265M 239M 229M 418M 28.3B 431M 2.82B 1.13B 13.57B 1.16B 1.13B 48.58B
Net income	-80.85M -69.43M -62.76M -60.09M -110M -7.43B -113M -739M -296M -3.56B -303M -297M -12.75B	-10.73M -9.21M -8.33M -7.97M -14.56M -985M -15.02M -98.09M -39.28M -472M -40.27M -39.41M -1.69B
Net Debt	-152M -131M -118M -113M -206M -13.96B -213M -1.39B -556M -6.69B -570M -558M -23.96B	-167M -143M -130M -124M -227M -15.34B -234M -1.53B -611M -7.35B -627M -613M -26.33B